Scientific content
Idorsia posters
The following two posters will be presented on February 5, 15:30 PST:
- Lucerastat, an investigational oral substrate reduction therapy in Fabry disease: Kidney biopsy results from the MODIFY open-label extension study (#125, Kiosk 14-B)
- Lucerastat effect on kidney function in patients with Fabry disease: Results from the ongoing open label-extension (OLE) of the phase 3 clinical program (#361. Kiosk 39-B)
We will make them available as pdf files after the session.
Additional information
On January 10, 2026, the results from the pivotal
Phase 3 MODIFY study and its open-label extension evaluating lucerastat, an oral substrate reduction therapy, in adults with Fabry disease were published in Nature Communications.